表紙:胃腸および消化による健康市場
市場調査レポート
商品コード
971226

胃腸および消化による健康市場

Gastrointestinals & Health Through Digestion

出版日: | 発行: Nicholas Hall & Company | ページ情報: 英文 | 納期: 即納可能 即納可能とは

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=154.38円
胃腸および消化による健康市場
出版日: 2021年02月01日
発行: Nicholas Hall & Company
ページ情報: 英文
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の胃腸とプロバイオティクスの市場規模は、2020年半ばまでの12か月で3.6%拡大し、約220億米ドルとなりました。同市場は、2029年には330億米ドル以上に達すると見込まれています。これは、現代のライフスタイル(不規則で不健康な食事パターンや、アルコール摂取量の増加を特徴とすることが多い)、消化状態に対する消費者の理解の高まり、主な発売活動、プロバイオティクスの健康上の利点、幅広い受け入れによって推進されています。

ただし、各市場とカテゴリーでの成分制限、自社ブランドやジェネリック医薬品との競合、特定の成熟したカテゴリーでの革新の欠如などは、同市場の抑制要因として挙げられます。

一方、消化による健康は、消費者ヘルスケアで最もホットなトピックの1つです。腸内細菌叢は、体の自然な防御を維持し、全体的な健康状態を高める上で最も重要です。主にプロバイオティクス、プレバイオティクス、シンバイオティクスなどの多くの製品は、免疫、体重管理、気分とストレス、皮膚の健康など、消化を超えた腸の健康関連の利点を提供します。また、進行中の腸脳軸研究は、健康における腸内細菌叢の拡大する役割に新たな光を投げかけています。

当レポートは、胃腸および消化による健康市場について調査しており、市場規模や動向、売上予測、成長要因、規制、トップラインの販売、ブランド実績、新たな開発・発売、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

エグゼクティブサマリー

  • 世界の概要
  • 競合情勢
  • カテゴリレビュー
  • 消化による健康
  • 見通し

ブラジル

  • 概要
  • 制酸剤
  • 抗鼓腸剤
  • 下剤
  • 止瀉薬
  • 消化酵素
  • 肝臓と胆汁の治療
  • 鎮痙薬とIBSの治療法
  • その他のGI
  • プロバイオティクス
  • 見通し

中国

フランス

ドイツ

インド

イタリア

日本

メキシコ

ロシア

米国

各市場の概要

  • カナダ
  • ポーランド
  • 韓国
  • 英国

ブランドのケーススタディ

  • Biostime
  • Dulcolax
  • Gaviscon
  • Pedialyte
  • Tums

展望と見通し

目次

Gastrointestinals, Probiotics & the Evolving Market for Health Through Digestion

KEY FEATURES OF THIS REPORT:

  • An in-depth exploration of the GIs and Probiotics market globally, including Antacids, Laxatives, Antidiarrhoeals, Liver & bile remedies, Digestive enzymes, Probiotics and more
  • Coverage of 10 major markets from around the world, with topline sales, brand performances, new developments, launches and promotional campaigns PLUS mini-profiles of additional markets
  • Very latest mid-year 2020 sales from DB6 , our dedicated CHC sales database, plus historical growth rates back to 2015
  • Case studies of key brands , highlighting strategies and success factors, sales, NPD activity and consumer & HCP promotion
  • Forecast sales to 2020 & 2021 for all categories and countries, plus longer-term predictions to 2024 & 2029

The global market for Gastrointestinals plus Probiotics expanded by 3.6% in the 12 months to mid-2020 to nearly $22bn; it is set to be worth over $33bn by 2029. It is being driven by modern lifestyles (often characterised by irregular unhealthy eating patterns and increased alcohol intake), rising consumer understanding of digestive conditions, limited but important launch activity, and wider acceptance of the health benefits of probiotics. Holding back growth are ingredient restrictions in selected markets and categories, brands facing competition from private labels & generics, and a lack of innovation in certain mature categories.

Health Through Digestion is one of the hottest topics in consumer healthcare. The gut microbiome is of central importance in maintaining the body's natural defences and boosting overall wellness. A host of products, primarily probiotics, prebiotics and synbiotics, offer gut health-related benefits beyond digestion such as immunity, weight management, mood & stress, skin health, and more. Ongoing research into the gut-brain axis (the biochemical signal between GI tract and central nervous system) casts fresh light on the expanding role of gut flora in health.

Key questions investigated in this report:

  • How do markets differ in terms of growth drivers, regulations and competitive landscape?
  • Which marketers and brands are performing best and what can be learned from their success?
  • What are the best examples of recent NPD and which developments will help expand the market in future?
  • How have sales been affected by the Covid-19 pandemic?
  • What are the latest findings related to Health through digestion?
  • Do gaps in the market still exist and who is best placed to seize future opportunities?

Covering all the issues affecting the GIs and Probiotics market, from consumer trends and regulatory changes to A+P campaigns and new product launch activity, this report spans 10 in-depth country profiles (generating over 70% of global sales between them) with insights and predictions, plus mini-profiles of additional markets .

New product developments are explored across markets, including Rx-to-OTC switches, delivery format innovations, line extensions, new benefits and more.

As part of the global overview, this report digs into the latest trends & developments in Health through digestion , including food intolerance and adult & infant nutrition.

Categories covered in this report:

  • Antacids
  • Antiflatulents
  • Laxatives
  • Antidiarrhoeals
  • Antinauseants
  • Digestive enzymes
  • Liver & bile remedies
  • Antispasmodics & IBS remedies
  • Traditional digestive remedies
  • Other GIs
  • Probiotics

selected markets only.

Brand case studies evaluate the key lessons to be learned from top brands, including consumer messaging, line extensions, portfolio development and brand strategies.

The report features the latest sales data from our dedicated DB6 database, including topline historical sales by region, country and category, and individual brand performances. Sales cover 12 months to mid-year 2020 (and mid-2019), plus historical growth rates back to 2015. The latest short-term forecasts to 2020 & 2021 and longer-term forecasts to 2024 & 2029 for each market and category are included.

Segmentation of sales in selected categories, including antacids, laxatives and probiotics, helps give a more detailed picture of each market.

10 individual markets covered:

  • Brazil
  • China
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Mexico
  • Russia
  • USA

PLUS coverage of selected additional markets in brief.

Table of Contents

Executive Summary

  • Global overview
  • Competitive landscape
  • Category review
  • Health through digestion
  • Outlook

Brazil

  • Overview
  • Antacids
  • Antiflatulents
  • Laxatives
  • Antidiarrhoeals
  • Digestive enzymes
  • Liver & bile remedies
  • Antispasmodics & IBS remedies
  • Other GIs
  • Probiotics
  • Outlook

China

  • Overview
  • Antacids
  • Laxatives
  • Antidiarrhoeals
  • Antinauseants
  • Digestive enzymes
  • Liver & bile remedies
  • Other GIs
  • Probiotics
  • Outlook

France

  • Overview
  • Antacids
  • Antiflatulents
  • Laxatives
  • Antidiarrhoeals
  • Antinauseants
  • Liver & bile remedies
  • Antispasmodics & IBS remedies
  • Other GIs
  • Probiotics
  • Outlook

Germany

  • Overview
  • Antacids
  • Antiflatulents
  • Laxatives
  • Antidiarrhoeals
  • Antinauseants
  • Digestive enzymes
  • Liver & bile remedies
  • Antispasmodics & IBS remedies
  • Other GIs
  • Probiotics
  • Outlook

India

  • Overview
  • Antacids
  • Laxatives
  • Antidiarrhoeals
  • Liver & bile remedies
  • Traditional digestive remedies
  • Probiotics
  • Outlook

Italy

  • Overview
  • Antacids
  • Antiflatulents
  • Laxatives
  • Antidiarrhoeals
  • Antinauseants
  • Liver & bile remedies
  • Antispasmodics & IBS remedies
  • Probiotics
  • Outlook

Japan

  • Overview
  • Antacids
  • Laxatives
  • Antidiarrhoeals
  • Antinauseants
  • Antispasmodics & IBS remedies
  • Traditional digestive remedies
  • Probiotics
  • Outlook

Mexico

  • Overview
  • Antacids
  • Antiflatulents
  • Laxatives
  • Antidiarrhoeals
  • Digestive enzymes
  • Liver & bile remedies
  • Antispasmodics & IBS remedies
  • Other GIs
  • Probiotics
  • Outlook

Russia

  • Overview
  • Antacids
  • Antiflatulents
  • Laxatives
  • Antidiarrhoeals
  • Antinauseants
  • Digestive enzymes
  • Liver & bile remedies
  • Antispasmodics & IBS remedies
  • Other GIs
  • Probiotics
  • Outlook

USA

  • Overview
  • Antacids
  • Antiflatulents
  • Laxatives
  • Antidiarrhoeals
  • Antinauseants
  • Digestive enzymes
  • Liver & bile remedies
  • Other GIs
  • Probiotics
  • Outlook

Selected markets in brief

  • Canada
  • Poland
  • South Korea
  • UK

Brand Case Studies

  • Biostime
  • Dulcolax
  • Gaviscon
  • Pedialyte
  • Tums

Outlook & Prospects